As we near the end of the discussion, I'd like to discuss adnexanet alpha relative to other new reversal agents.
A recent correspondence to the NEJM described a new agent, PER977, that binds and reverses edoxaban. This agent is not specific to factor Xa inhibitors and has potential for use in dabigatran as well. While this agent has not been studied in healthy volunteers yet, it seems to have significant potential. Perhaps we can discuss how they are similar, and where they differ.
Dr. Ansell, perhaps you can discuss PER977, since you were the lead author on the NEJM correspondence.